Serial #98404547
LIVE

Serial Number

98404547

Owner

Sosei Group Corporation

Attorney

Eric Lamb

Filing Date

Feb 13, 2024

Add to watchlist:

No watchlists yet
View on USPTO

Serial #98404547 Trademark

Serial Number: 98404547 • Registration: 8106108

Serial #98404547 is a trademark filed by Sosei Group Corporation on February 13, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Sosei Group Corporation (13 trademarks)

2-4 Kojimachi, Chiyoda-ku

Entity Type: 98

NXERA PHARMA CO., LTD

9-7-2 AKASAKA MINATO-KU
TOKYO 107-0052 , JP

Entity Type: 99

Trademark Details

Filing Date

February 13, 2024

Registration Date

January 20, 2026

Published for Opposition

December 2, 2025

Goods & Services

Business management, business organization consulting, and business administration, all provided in the fields of chemical products, biological products, pharmaceuticals, design and development of drugs, and drug discovery; Business management, business organization consulting, and business administration, all provided in the field of pharmaceutical and biopharmaceutical research and development, and field of technologies related to proteins and G-protein-coupled receptors; wholesale and retail store services featuring pharmaceuticals, biological products and chemical and biological preparations

Drug discovery services and pharmaceutical discovery services being pharmaceutical research services; Biotechnology research; pharmaceutical research services; chemical and medical testing in the nature of testing of chemicals; research, development, advice, consultancy and information services, namely, design and testing of new products for others; research and development services in the field of pharmaceutical preparations being pharmaceuticals and biopharmaceuticals and field of pharmaceutical preparations being technologies related to proteins and G-protein-coupled receptors; pharmaceutical research services in the fields of chemical and biological drug discovery and development; pharmaceutical research services and pharmaceutical products development for identifying lead chemical compounds; examination and research services being pharmaceutical research services in the field of medicinal and synthetic chemistry; scientific research and development services in the fields of creation of libraries and collections of biologicals, chemicals and compounds; research, creation, and development, namely, scientific research and development in the field of chemical and biological drug targets for screening purposes; research, analysis and examination, namely, scientific research and development in the field of identification of compounds through automated screening processes; scientific research and development services in the field of chemical and biological pharmaceutical development; medical research laboratory services; provision of information, advisory services and consultancy in connection with all of the aforesaid services

Pharmaceutical preparations for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; medicines for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; biological products for medical purposes, namely, medicinal preparations being G-protein-coupled receptors for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the fields of chemical and biological drug discovery, lead identification, diagnostics and therapeutic purposes; biological and chemical products for medical use, namely, protein supplements; biological and chemical products for medical use, namely, medicinal preparation being G-protein-coupled receptors for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; biological and chemical products for medical use, namely, medicinal preparation being transmembrane proteins for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; biological and chemical products for medical use, namely, medicinal preparation being G-proteins for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; biological and chemical products for medical use, namely, antibodies for medical purposes and synthetic peptides and parts thereof being synthetic peptides for therapeutic purposes for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; chemical reagents for medical use and protein supplements for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of medical diagnostics; biological products being medicinal preparations for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of chemical and biological drug discovery, and in the field of lead identification and diagnostics; biological products being medicinal preparations for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for therapeutic purposes; biological formulation being medicinal preparations for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of developing chemical and biological pharmaceutical products; biological formulation being medicinal preparations for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of identifying lead chemical and biological products; biological formulation being medicinal preparations for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for diagnostic use; biological formulation being medicinal preparations for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for therapeutic use; protein supplements and medicinal preparations being G-protein-coupled receptors, both for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of drug discovery purposes; biological reagents for medical purposes and medicinal preparations being small chemical entities for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; medicinal preparations being G-protein-coupled receptors for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; medicinal preparations being transmembrane proteins for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; medicinal preparations being G-proteins for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; antibodies for medical purposes and synthetic peptides for therapeutic purposes for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; protein supplements for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; antibodies for medical purposes and synthetic peptides for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders in the field of medical diagnostics

Chemical products and proteins both for use in the manufacture of industrial chemicals and biological pharmaceutical products; chemical products being industrial chemicals and protein in raw material form for scientific and medical research being research of chemical and biological pharmaceutical products; chemical products being industrial chemicals and proteins for industrial use in the field of diagnostic use, except medical or veterinary uses; protein for industrial use and G-protein coupled receptors being protein for industrial use for manufacturing pharmaceutical products; protein for industrial use and G-protein-coupled receptors being protein for industrial use for the research of pharmaceutical products; industrial chemicals and protein for industrial use for use in the fields of chemical and biological drug discovery, lead identification and diagnostics; protein for industrial use and G-protein-coupled receptors being protein for industrial use for drug discovery purposes; industrial chemicals and biologicals in the nature of protein for industrial use, transmembrane proteins and G-proteins both being protein for industrial use, G-protein-coupled receptors being protein for industrial use, and fragments thereof being sequences of amino acids in the nature of amino acids, other than for medical or veterinary purposes, for use in the fields of chemical and biological drug discovery, lead identification and diagnostics; protein for industrial use in the nature of transmembrane proteins and G-proteins both being protein for industrial use, G-protein-coupled receptors being protein for industrial use, and fragments thereof being sequences of amino acids in the nature of amino acids, other than for medical or veterinary purposes, for use in the fields of pharmaceutical research and drug discovery purposes

Pharmaceutical compounding services; pharmaceutical advice and medical and pharmaceutical consultation; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical and pharmaceutical consultation in the fields of research, creation, development and provision of chemical and biological drug targets for medical screening purposes; all of the aforesaid services provided in the field of drug discovery and field of use of G-protein- coupled receptors in the design and development of pharmaceutical products

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 20, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 20, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 2, 2025 NPUB
PUBLISHED FOR OPPOSITION
Dec 2, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 26, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 31, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 31, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 31, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 31, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 31, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 23, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 23, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 23, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 25, 2025 GNFN
FINAL REFUSAL E-MAILED
Jun 25, 2025 GNFR
FINAL REFUSAL WRITTEN
Jun 25, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 1, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 28, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 28, 2025 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 12, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 12, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 12, 2024 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 2, 2024 GNRN
NON-FINAL ACTION E-MAILED
Dec 2, 2024 GNRT
NON-FINAL ACTION WRITTEN
Dec 2, 2024 CNRT
ASSIGNED TO EXAMINER
Jul 16, 2024 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 4, 2024 ASGN
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 25, 2024 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 25, 2024 NWOS
NEW APPLICATION ENTERED
Feb 13, 2024 NWAP